Skip to content

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.: 10-Q filed 2026-02-19

What CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC. reported in its quarterly report filed 2026-02-19 (fiscal Q2 2026): 30 published measures, 94 facts as tagged in accession 0001683168-26-001190.

This filing

Form
10-Q (quarterly report)
Filed
2026-02-19
Fiscal period
fiscal Q2 2026
Accession
0001683168-26-001190 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-11-3022,131USD
At 2025-05-3131,880USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-11-301,385,326USD
At 2025-05-311,195,463USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-11-30-1,363,195USD
At 2025-08-31-1,246,228USD
At 2025-05-31-1,163,583USD
At 2024-11-30-1,134,846USD
At 2024-08-31-1,055,317USD
At 2024-05-31-1,079,013USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-116,966USD91
2025-06-01 to 2025-11-30-199,612USD183
2025-06-01 to 2025-08-31-82,645USD92
2024-09-01 to 2024-11-30-79,528USD91
2024-06-01 to 2024-11-30-155,833USD183
2024-06-01 to 2024-08-31-76,305USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-06-01 to 2025-11-30-109,205USD183
2024-06-01 to 2024-11-30-102,503USD183

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-09-01 to 2025-11-3053,266USD91
2025-06-01 to 2025-11-3077,466USD183
2024-09-01 to 2024-11-3074,248USD91
2024-06-01 to 2024-11-30253,135USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-11-30-6,082,513USD
At 2025-05-31-5,882,901USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-09-01 to 2025-11-3011,626,749,347shares91
2025-06-01 to 2025-11-3011,626,749,347shares183
2024-09-01 to 2024-11-3010,497,459,730shares91
2024-06-01 to 2024-11-3010,497,459,730shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-09-01 to 2025-11-3011,626,749,347shares91
2025-06-01 to 2025-11-3011,626,749,347shares183
2024-09-01 to 2024-11-3010,497,459,730shares91
2024-06-01 to 2024-11-3010,497,459,730shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-0.00001USD/shares91
2025-06-01 to 2025-11-30-0.000017USD/shares183
2024-09-01 to 2024-11-30-0.000008USD/shares91
2024-06-01 to 2024-11-30-0.000002USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-0.00001USD/shares91
2025-06-01 to 2025-11-30-0.000017USD/shares183
2024-09-01 to 2024-11-30-0.000008USD/shares91
2024-06-01 to 2024-11-30-0.000002USD/shares183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-95,877USD91
2025-06-01 to 2025-11-30-170,661USD183
2024-09-01 to 2024-11-30-59,627USD91
2024-06-01 to 2024-11-30-157,231USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-11-3022,131USD
At 2025-05-3129,085USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-11-301,135,826USD
At 2025-05-31945,963USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-11-3021,811USD
At 2025-05-316,380USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-09-01 to 2025-11-30138,643USD91
2025-06-01 to 2025-11-30229,484USD183
2024-09-01 to 2024-11-30126,072USD91
2024-06-01 to 2024-11-30394,201USD183

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-09-01 to 2025-11-3042,766USD91
2025-06-01 to 2025-11-3058,823USD183
2024-09-01 to 2024-11-3066,445USD91
2024-06-01 to 2024-11-30236,970USD183

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-09-01 to 2025-11-3010,500USD91
2025-06-01 to 2025-11-3018,643USD183
2024-09-01 to 2024-11-307,803USD91
2024-06-01 to 2024-11-3016,165USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-11-3011,626,749,347shares
At 2025-05-3111,626,749,347shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-11-30132USD
At 2025-05-3112,952USD
At 2024-11-301,002USD
At 2024-05-31755USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-11-304,719,318USD
At 2025-05-314,719,318USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-11-300USD
At 2025-05-312,795USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-11-300USD
At 2025-05-314,906USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2025-11-30291,225USD
At 2025-05-31286,187USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-09-01 to 2025-11-3030,972USD91
2025-06-01 to 2025-11-3054,280USD183
2024-09-01 to 2024-11-3040,128USD91
2024-06-01 to 2024-11-30101,424USD183

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-09-01 to 2025-11-3017,860USD91
2025-06-01 to 2025-11-3035,228USD183
2024-09-01 to 2024-11-308,701USD91
2024-06-01 to 2024-11-3011,040USD183

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-09-01 to 2025-11-30-21,090USD91
2025-06-01 to 2025-11-30-28,952USD183
2024-09-01 to 2024-11-30-19,901USD91
2024-06-01 to 2024-11-301,398USD183

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-06-01 to 2025-11-3035,228USD183
2024-06-01 to 2024-11-3011,040USD183

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-06-01 to 2025-11-300USD183
2024-06-01 to 2024-11-300USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-06-01 to 2025-11-3015,431USD183
2024-06-01 to 2024-11-30-6,320USD183

Inspect the source

Entity
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC. / CIK 0001411057
Captured
2026-09-20T08:01:51.094Z
SEC response SHA-256
65039acad959501dea2ae2bfec13b3503da3ac05045712ff74cd71cfd51e2523

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411057.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))